Article | Published:

ZNF326 promotes proliferation of non-small cell lung cancer cells by regulating ERCC1 expression

Laboratory Investigationvolume 99pages169179 (2019) | Download Citation

Abstract

The roles and downstream target genes of the transcription factor ZNF326 in malignant tumors are unclear. Out of 146 lung cancer tissue samples, we found that high expression of ZNF326 in 82 samples was closely related to low differentiation and a high pTNM stage of non-small cell lung cancer (NSCLC) cells. In vitro and in vivo analyses showed that ZNF326 significantly promoted cell cycle progression, colony formation, and proliferation as well as the growth of NSCLC transplanted tumors. Chromatin immunoprecipitation sequencing, dual-luciferase assay, and electrophoretic mobility shift assay confirmed that the C2H2 structure of ZNF326 binds to the −833 to −875 bp region of the ERCC1 promoter to initiate transcriptional activity. This binding promoted CyclinB1 synthesis and cell cycle progression. These results show that the ZNF326 transcription factor is highly expressed in lung cancer and promotes the proliferation of NSCLC cells by regulating the expression of ERCC1.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin. 2015;65:87–108.

  2. 2.

    Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomark Prev. 2016;25:16–27.

  3. 3.

    Chen WQ, Zuo TT, Zheng RS, et al. Lung cancer incidence and mortality in China in 2013. Zhonghua Zhong Liu Za Zhi. 2017;39:795–800.

  4. 4.

    Jen J, Lin LL, Chen HT, et al. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 2016;35:2357–69.

  5. 5.

    Li K, Zhu ZC, Liu YJ, et al. ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299. Int J Clin Exp Pathol. 2013;6:2460–7.

  6. 6.

    Rangel R, Guzman-Rojas L, Kodama T, et al. Identification of new tumor suppressor genes in triple-negative breast cancer. Cancer Res. 2017;7:4089–101.

  7. 7.

    Rengasamy M, Zhang F, Vashisht A, et al. The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. Nucleic Acids Res. 2017;45:11106–20.

  8. 8.

    Close P, East P, Dirac-Svejstrup AB, et al. DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation. Nature. 2012;484:386–9.

  9. 9.

    Lee JY, Kambe M, Hayashi M, et al. Cloning and characterization of a novel zinc finger protein that associates with nuclear matrix. DNA Cell Biol. 1998;17:849–58.

  10. 10.

    Travis WD, Brambilla E, Burke AP, et al. WHO classification of tumours of the lung, pleura, thymus, and heart. 4th ed. Lyon: IARC; 2015. p. 10–5.

  11. 11.

    Yang L, Wang S, Zhou Y, et al. Evaluation of the 7(th) and 8(th) editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget. 2017;40:66784–95.

  12. 12.

    Andrieux LO, Fautrel A, Bessard A, et al. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res. 2007;67:2114–23.

  13. 13.

    Lee JY, Nakane Y, Koshikawa N, et al. Characterization of a zinc finger protein ZAN75: nuclear localization signal, transcriptional activator activity, and expression during neuronal differentiation of P19 cells. DNA Cell Biol. 2000;19:227–34.

  14. 14.

    Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007;356:2538–40.

  15. 15.

    Dudás J, Schartinger VH, Romani A, et al. Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. Tumour Biol. 2014;35:7807–19.

  16. 16.

    Vaezi AE, Bepler G, Bhagwat NR, et al. Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer. 2014;120:1898–907.

  17. 17.

    Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, et al. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. Pathol Res Pract. 2018;214:44–52.

  18. 18.

    Lindsey-Boltz LA. Bringing it all together: coupling excision repair to the DNA damage checkpoint. Photochem Photobiol. 2017;93:238–44.

  19. 19.

    Núñez F, Chipchase MD, Clarke AR, et al. Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21. FASEB J. 2000;14:1073–82.

  20. 20.

    Gao SY, Li J, Qu XY, et al. Downregulation of Cdk1 and cyclinB1 expression contributes to oridonin-induced cell cycle arrest at G2/M phase and growth inhibition in SGC-7901 gastric cancer cells. Asian Pac J Cancer Prev. 2014;15:6437–41.

  21. 21.

    Feng W, Cai D, Zhang B, et al. Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and CyclinB1/Cdk1 in pancreatic cancer cells. Biomed Pharmacother. 2015;8:257–64.

  22. 22.

    Cheng YM, Tsai CC, Hsu YC. Sulforaphane, a dietary isothiocyanate, induces G2/M arrest in cervical cancer cells through CyclinB1 downregulation and GADD45β/CDC2 association. Int J Mol Sci. 2016;17:12.

  23. 23.

    Xia YQ, Wei XY, Li WL, et al. Curcumin analogue A501 induces G2/M arrest and apoptosis in non-small cell lung cancer cells. Asian Pac J Cancer Prev. 2014;15:6893–8.

Download references

Acknowledgements

The ZNF326 interference target sequence was donated by Professor Roberto Rangel at the Anderson Cancer Center, University of Texas. This study was supported by the National Natural Science Foundation of China (No. 81572854 and No. 81772489, Wang Enhua).

Author information

Affiliations

  1. Department of Pathology, College of Basic Medical Sciences and First Affiliated Hospital, China Medical University, Shenyang, PR China

    • Jingjing Wu
    • , Xiupeng Zhang
    • , Qiang Han
    • , Xu Han
    • , Xuezhu Rong
    • , Xiaoying Zheng
    •  & Enhua Wang
  2. Neurosurgery, The First Affiliated Hospital, China Medical University, Shenyang, PR China

    • Minghao Wang

Authors

  1. Search for Jingjing Wu in:

  2. Search for Xiupeng Zhang in:

  3. Search for Qiang Han in:

  4. Search for Xu Han in:

  5. Search for Xuezhu Rong in:

  6. Search for Minghao Wang in:

  7. Search for Xiaoying Zheng in:

  8. Search for Enhua Wang in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Enhua Wang.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41374-018-0148-y